Evidence map›Paper›PMID 37505750›Full record

SynthesisAsian Pacific journal of cancer prevention : APJCP2023

What is the Role of SNORA42 in Carcinogenesis? A Systematic Review.

Eldevan Da Silva Barbosa, Ana Gabrielly De Melo Matos, Marcelli Geisse De Oliveira Prata Da Silva, Matheus Silva Alves, Antonio Augusto Lima Teixeira-Júnior, Wesliany Everton Duarte, Alania Frank Mendonça, Carolina Rosal Teixeira De Souza, Marcelo Souza De Andrade, André Salim Khayat and 2 more

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Eldevan Da Silva BarbosaState University of Maranhão, Campus Zé Doca, Zé Doca, Brazil.
Ana Gabrielly De Melo MatosState University of Maranhão, Campus Bacabal, Bacabal, Brazil.
Marcelli Geisse De Oliveira Prata Da SilvaOncology Research Center, Federal University of Pará, Belém, Brazil.
Matheus Silva AlvesState University of the Tocantina Region of Maranhão, Imperatriz, Brazil.
Antonio Augusto Lima Teixeira-JúniorFaculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
Wesliany Everton DuartePitágoras College, Bacabal, Brazil.
Alania Frank MendonçaState University of Maranhão, Campus Zé Doca, Zé Doca, Brazil.
Carolina Rosal Teixeira De SouzaOncology Research Center, Federal University of Pará, Belém, Brazil.
Marcelo Souza De AndradeFederal University of Maranhão, São Luis, Brazil.
André Salim KhayatOncology Research Center, Federal University of Pará, Belém, Brazil.
Juliana Maria Trindade BezerraState University of Maranhão, Campus Lago da Pedra, Lago da Pedra, Brazil.
Jaqueline Diniz PinhoState University of Maranhão, Campus Zé Doca, Zé Doca, Brazil.
Universidade Federal do Pará · BRUniversity of Zenica · BAUniversidade Estadual da Região Tocantina do Maranhão · BRUniversidade Federal do Maranhão · BRUniversidade de São Paulo · BRUniversidade Estadual Paulista (Unesp) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePerform a systematic literature review on SNORA42 in carcinogenesis in order to elucidate its importance, its potential use as a biomarker and as a therapeutic target.

methodsUsing PubMed, SciELO and Science Direct databases as search means, articles that are in line with the scope of the study, written in English, that were published between 2012 and 2022, were selected using the following keywords: "small nucleolar RNA 42", "snoRNA 42" and "SNORA42", as well as searches for the synonyms of this snoRNA (SNORA80E, box H/ACA 42 and ACA42).

resultFrom a total of 131 studies, seven were selected, in which it was possible to identify that SNORA42 interferes in several biological processes, such as proliferation, migration, invasion, metastasis, apoptosis, and signaling pathways. Among the signaling pathways, the p53 and NF-KappaB pathways stand out. Moreover, it is a potential biomarker for diagnosis, prognosis, and treatment of cancer.

conclusionThe summary of the main information about SNORA42 in the process of carcinogenesis and cancer progression shows that the use of this snoRNA is ideal for future applications in the field of oncology, in which it can be used as a biomarker and therapeutic target. Thus, it is of fundamental importance to carry out new studies to consolidate the applicability of this molecule.

Indexed as

CarcinogenesisRNA, Small NucleolarApoptosisHumansPrognosisRNA, Small NucleolarBiomarkermalignant neoplasmssnoRNA

Identifiers

PMID37505750
PMCPMC10676506
OpenAlexW4385331548

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.